Overview
- The plant will be located at Leiden Bio Science Park in Katwijk, with construction scheduled to begin next year.
- It is expected to add about 500 skilled manufacturing roles and roughly 1,500 construction jobs.
- The facility will also produce oral medicines for cardiometabolic, neurological, oncology and immunology conditions.
- The announcement follows a more than $1.2 billion expansion in Carolina, Puerto Rico, under Lilly’s $50 billion U.S. manufacturing plan, with two additional U.S. sites to be named in the coming months.
- Lilly says it has invested billions to scale output as it prepares global orforglipron submissions by year-end, and last week reported the pill met most criteria for an FDA priority review voucher that could cut review times to one or two months from about 10 to 12.